Marjolein V. D. P.
- Country
- The Netherlands
- Department
- Hematology
Research Overview
- A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cells (GLPG5301; BCMACP03) in subjects with relapsed/refractory Multiple Myeloma (RRMM)
- Long-term Efficacy and Safety of Belzutifan and Lenvatinib in Patients with von Hippel-Lindau Disease-Associated Tumors and Other Advanced Solid Tumors
- A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 (19CP02) in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma
Data & Insights
Has run more than one trial at 279 of 537 partner sites.
Specializations
Lymphoma Research Focus
This investigator specializes in the treatment of B-cell lymphomas, with particular emphasis on Non-Hodgkin Lymphoma (NHL) variants. Their research encompasses innovative therapeutic approaches for both newly diagnosed and relapsed/refractory cases.
- B-cell Lymphoma Therapeutics
- Novel Treatment Combinations
- Refractory Disease Management
Specialized Lymphoma Subtypes
The investigator has developed expertise in treating specific lymphoma subtypes, including Diffuse Large B-Cell Lymphoma (DLBCL) and Mantle Cell Lymphoma. Their work involves evaluating targeted therapies and combination treatment strategies.
- DLBCL Treatment Protocols
- Mantle Cell Lymphoma Management
- Progressive Disease Interventions
Treatment Innovation
The investigator explores novel therapeutic agents and their integration with established treatments. Their research includes evaluation of antibody-based therapies and targeted molecular approaches in lymphoma treatment.
- Combination Therapy Development
- Immunotherapy Applications
- Treatment Response Assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.